Market openNon-fractional

Collegium Pharmaceutical/COLL

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Collegium Pharmaceutical

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Ticker

COLL

Sector

Healthcare

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

Stoughton, United States

Employees

197

COLL Metrics

BasicAdvanced
$1.1B
Market cap
13.98
P/E ratio
$2.32
EPS
1.05
Beta
-
Dividend rate
$1.1B
1.05
2.058
1.88
200.588
283.564
2.72%
10.56%
46.43%
13.975
1.898
4.72
-3.51
3.491
8.00%
-367.67%
20.85%
25.28%

What the Analysts think about COLL

Analyst Ratings

Majority rating from 6 analysts.
Hold

COLL Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
19.11% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$145M
-3.21%
Net income
$28M
-13.17%
Profit margin
19.11%
-10.28%

COLL Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 54.50%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.34
$0.53
$0.82
$1.45
-
Expected
$0.29
$0.52
$0.66
$0.94
$1.49
Surprise
18.26%
2.58%
24.24%
54.50%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market openNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Collegium Pharmaceutical stock?

Collegium Pharmaceutical (COLL) has a market cap of $1.1B as of July 05, 2024.

What is the P/E ratio for Collegium Pharmaceutical stock?

The price to earnings (P/E) ratio for Collegium Pharmaceutical (COLL) stock is 13.98 as of July 05, 2024.

Does Collegium Pharmaceutical stock pay dividends?

No, Collegium Pharmaceutical (COLL) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next Collegium Pharmaceutical dividend payment date?

Collegium Pharmaceutical (COLL) stock does not pay dividends to its shareholders.

What is the beta indicator for Collegium Pharmaceutical?

Collegium Pharmaceutical (COLL) has a beta rating of 1.05. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Collegium Pharmaceutical stock

Buy or sell Collegium Pharmaceutical stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing